Hormone replacement therapy in relation to the risk of colorectal cancer in women by BMI: a multicentre study with propensity score matching

• Published in: International journal of clinical oncology 2022-04, Vol.27 (4), p.765-773
• Main Authors: Xu, Lingkai, Li, Lin, Xu, Dongkui, Qiu, Junlan, Feng, Qingting, Wen, Tao, Lu, Shun, Meng, Fang, Shu, Xiaochen
• Format: Article
• Language: English
• Subjects: Body Mass Index; Cancer; Cancer Research; Carcinogenesis; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - epidemiology; Epidemiology; Estrogen Replacement Therapy - adverse effects; Estrogens; Female; Hormone replacement therapy; Hormone Replacement Therapy - adverse effects; Humans; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Article; Propensity Score; Retrospective Studies; Risk Factors; Surgical Oncology; Tumorigenesis
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-021-02110-8

Background Epidemiological evidence about hormone replacement therapy and colorectal carcinogenesis by demographic and clinical traits remains unclear. We aimed to assess this postulated association in a large multicentre study and further explore the modification effect by BMI and others. Methods We retrospectively collected records of women diagnosed with colorectal cancer (CRC) at the age of 50 years and older during 2014–2017 and their HRT dispensing prior to CRC diagnosis in three tertiary hospitals in China. CRC cases were matched with controls at a ratio of 1:3 using nearest neighbour propensity scores matching to better control for the remaining imbalance between groups, which generated a total of 824 cases with 2472 controls. Results Our study confirmed the inversed association between colorectal cancer risk and hormone replacement therapy (OR, 0.62; 95% CI, 0.54–0.75), which was more prominent among women having multiple HRT dispenses (OR, 0.60; 95% CI, 0.52–0.76). Furthermore, significant associations were consistently observed for the short-term (OR, 0.69; 95% CI, 0.57–0.88), middle-term (OR, 0.51; 95% CI, 0.41–0.66), and long-term HRT users (OR, 0.70; 95% CI, 0.43–0.90). Estrogen-related regimen reduced CRC risk more than progestogen-only. We, for the first time, found that the modifying effect of BMI on HRT use and CRC risk was in different ways when BMI was categorized by a medium level of 27. Conclusion Our findings mainly suggest that there might be a different mechanism for the reversed association between HRT and colorectal tumorigenesis by BMI level, providing thoughts on clinical treatment of CRC.